Toronto, Ontario – April 26, 2023, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers released its audited annual consolidated 2022 financial statements. Financial Summary: For the year ended December 31st: Audited Consolidated Statements of Operations             (In Canadian Dollars)    2022 2021 % Change   Revenue       Canada 1,007,841 697,727 44% United States 112,041 69,725 61% International 18,687 13,189 42% Total Revenue 1,138,569 780,641 46%         Cost of Sales 510,395 470,698 8% Gross Margin 628,174 309,943 103% Gross Margin (% of revenue) 55% 40%           Operating Expenses       Selling Expenses 301,359 363,886 -17% Administrative Expenses 1,277,253 1,562,867 -18% Research and Development Expenses – CLT Division 167,365 308,708 … Read More

Toronto, Ontario – February 23, 2023,Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, announced today that its Phase II clinical study (“Study II”) interim data was recently presented at the American Society of Clinical Oncology (“ASCO”) Genito Urinary (“GU”) Cancer Symposium via a moderated poster presentation. Study II has been designed to treat patients diagnosed with Bacillus Calmette-Guérin (“BCG”)-Unresponsive, Non-Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”) (with or without resected papillary Ta/T1 disease) with a patented investigational study drug (TLD-1433) (Trade Name: Ruvidar™), a ruthenium based PDC intravesically instilled into a patient’s bladder, then subsequently activated by a proprietary investigational study device (TLC-3200), a green (520 nm) laser system equipped with fiber-optic light emitters … Read More